Home
About
Directors and Management
Careers
Corporate Governance
Board Charter
Code of Conduct
Audit Committee Charter
Nomination and Remuneration Committee Charter
Continuous Disclosure Policy
Share Trading Policy
Risk Management Policy
Social Media Policy
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
Whistleblower Policy
Investors
Public Disclosure Policy
ASX Announcements
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Contact
Shop évolis®
✕
The New Biotech Reports on Cellmid Limited
Home
The New Biotech Reports on Cellmid Limited
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
$26M Capped ASX Stock Generating Millions in Revenue
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
New ASX Listing: $15M Capped Stock with phase 2 Trialled Cancer Drug
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
US Sales unlocked for CDY: Pathway to $100M Revenue in Near Term
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
CDY Sales up to 72%: $100M Targets in Place
November 15, 2019
Published by
Tiffany McMillan
on
November 15, 2019
Categories
CDY Backs Hair research growth for 2017 as it capitalizes on US entry
Shop évolis®
